This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Farnesyl transferase; geranylgeranyltransferase I (PGGT1B; GGTase I)	<p>A study in mice suggests that antagonizing both farnesyl transferase and GGTase I could help treat cancer. In mice with an activating mutation in K-Ras, genetic inactivation of both farnesyl transferase and GGTase I reduced the size and number of tumors more effectively than farnesyl transferase inactivation alone. Next steps include the development of dual inhibitors of farnesyl transferase and GGTase I.</p> <p>Johnson & Johnson's Zarnestra tipifarnib, a farnesyl transferase antagonist, is in registration to treat acute myelogenous lymphoma (AML) and in Phase III trials for colorectal cancer and pancreatic cancer. Tigris Pharmaceutical Inc.'s GGTase I inhibitor, GTI-2418, is in Phase I for solid tumors.</p> <p>SciBX 3(15); doi:10.1038/scibx.2010.460 Published online April 15, 2010</p>	Unpatented; licensing status not applicable	<p>Liu, M. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online March 22, 2010; doi:10.1073/pnas.0908396107</p> <p>Contact: Martin O. Bergo, Sahlgrenska University Hospital, Gothenburg, Sweden e-mail: martin.bergo@wlab.gu.se</p>